Download
1 / 1
10 likes | 135 Views
The IMAGINE trial investigated the impact of early initiation of quinapril, an ACE inhibitor, following coronary artery bypass grafting (CABG) in patients with preserved left ventricular function. Over a median follow-up of 2.95 years, the composite incidence of cardiovascular death, cardiac arrest, nonfatal myocardial infarction, coronary revascularization, unstable angina, heart failure, angina, and stroke was 13.7% in the quinapril group compared to 12.2% in the placebo group, showing no significant improvement in clinical outcomes, particularly in low-risk patients.
E N D
IMAGINE Incidence of CV death, resuscitated cardiac arrest, nonfatal MI, coronary revascularization, unstable angina or heart failure, angina, and stroke 13.7% in quinapril group and 12.2% in placebo group (HR 1.15, 95% CI 0.92-1.42; p = 0.212) over a median duration of 2.95 years Primary composite endpoint significantly increased in the first 3 months after CABG in quinapril group (p = 0.04) Trial design: IMAGINE was a double-blinded, randomized, placebo-controlled trial designedto test the effects of early ACE inhibitor initiation (quinapril 10 or 20 mg/day within 7 to 10 days) after CABG in patients with preserved LV function, and no clear indication for ACE inhibitor therapy. Results CV death or cardiac arrest (p = 0.57) 0.6 0.4 0.2 0 0.5 0.4 % Conclusions • In patients at low risk of CV events after CABG, routine early initiation of ACE inhibitor therapy does not appear to improve clinical outcome up to 3 years after CABG Quinapril (n = 1,280) Placebo (n = 1,273) Rouleau JL, et al. Circulation 2008;117:24-31
